Intra-Cellular Therapies Reports Narrower Q1 Loss, Revenue Higher
08:19 AM EDT, 05/10/2021 (MT Newswires) -- Intra-Cellular Therapies (ITCI) on Monday reported a net loss of $0.65 per share in Q1 compared with a loss of $0.73 per share in the previous year. Analysts surveyed by Capital IQ were expecting a net loss of $0.80 per share.
Revenue amounted to $15.9 million, up from $1.1 million a year ago. Analysts were expecting revenue of $16.9 million.
Cash, cash equivalents, restricted cash and investment securities amounted to $613.4 million at the end of Q1, down from $658.8 million at the end of the prior quarter.
Price: 35.03, Change: +1.60, Percent Change: +4.79